Insights on the therapeutic use of ivermectin: Mechanism of action and histopathological effects
Keywords:Ivermectin, Histopathology , Mechanism of action
Ivermectin is a broad-spectrum antiparasitic drug with outstanding efficacy and a wide margin of safety. This drug has been widely utilized in veterinary medicine since 1987, and its use in humans has grown. Ivermectin is a broad-spectrum anti-parasitic agent licensed by the FDA. Ivermectin is a mixture of 80% or more avermectin B1a (AB1a) analogue and 20% or less avermectin B1b analogue. Iverzine has been proven to have widespread antiviral action in recent years. Ivermectin has also a broad-spectrum activity against the viruses that cause dengue, Zika, HIV, and yellow fever in vitro. Despite this in vitro action, no clinical trials have shown that ivermectin has a therapeutic benefit in patients with these viruses. Some ivermectin studies have also revealed potential anti-inflammatory qualities, which may be beneficial in persons with COVID-19. However, the use of ivermectin in animals was also associated with some histopathological effects in the internal organs including the liver, kidney, spleen, and brain. The purpose of this review was to provide light on the mechanism of action of ivermectin and its related histopathological consequences in various animal species.
How to Cite
Copyright (c) 2024 Journal of Advanced Veterinary Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles under the following conditions: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license